Zacks Investment Research downgraded shares of ONCONOVA THERAP (ONTX) from OUTPERFORM to NEUTRAL on February 05, 2015, with a target price of $3.10.
Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania.
To get a free copy of the research report on ONCONOVA THERAP (ONTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment